Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 10:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 71 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Dose Response Relationship, Drug Clear all
Completed Phase 2 Interventional

The Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3

NCT00000825
View directory record Official record
Conditions
HIV Infections
Interventions
Aldesleukin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Jul 23, 2026, 10:53 AM EDT
Completed Phase 1 Interventional

A Phase I Clinical Trial To Evaluate the Toxicity, Antiviral and Immunomodulatory Effects of a Range of Doses of Ampligen in HIV-Infected Subjects

NCT00000713
View directory record Official record
Conditions
HIV Infections
Interventions
Ampligen
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1992
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Jul 23, 2026, 10:53 AM EDT
Completed Not applicable Interventional

An Oral Dose-Ranging Finding Study in Patients With HIV Disease, CDC Classification Groups IIB, III, and IV-C2

NCT00002023
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 23, 2026, 10:53 AM EDT
Completed Phase 1 Interventional

A Study to Test the Safety of Recombinant Interleukin-2 (rIL-2) in HIV-Infected Children

NCT00000849
View directory record Official record
Conditions
HIV Infections
Interventions
Aldesleukin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 12 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2001
U.S. locations
14
States / cities
Long Beach, California • San Francisco, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Jul 23, 2026, 10:53 AM EDT
Completed Phase 1 Interventional

A Study of AZT Plus Human Interferon Alpha in the Treatment of AIDS-Related Kaposi's Sarcoma

NCT00001113
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Interferon alfa-2a, Zidovudine, Interferon alfa-n1
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1990
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Jul 23, 2026, 10:53 AM EDT
Completed Phase 1 Interventional

A Study of CI-1012 in HIV-Infected Patients

NCT00002196
View directory record Official record
Conditions
HIV Infections
Interventions
CI-1012
Drug
Lead sponsor
Parke-Davis
Industry
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
4
States / cities
Palm Springs, California • San Francisco, California • Maitland, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 23, 2026, 10:53 AM EDT
Completed Phase 1 Interventional

Interleukin-2 Plus Anti-HIV Therapy in HIV-Infected Children With Weakened Immune Systems

NCT00006066
View directory record Official record
Conditions
HIV Infections
Interventions
Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed, Diphtheria and Tetanus Toxoids Adsorbed, Tetanus and Diphtheria Toxoids Adsorbed, Bacteriophage phi X 174, Aldesleukin
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 18 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
13
States / cities
Long Beach, California • Los Angeles, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Jul 23, 2026, 10:53 AM EDT
Completed Phase 1 Interventional

Safety and Tolerance of Indinavir Plus Ritonavir in HIV-Positive Patients Failing Therapy With Amprenavir, Nelfinavir, or Saquinavir

NCT00001133
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Ritonavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
7
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Jul 23, 2026, 10:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to See Whether Two HIV Vaccines Are Safe and Can Prevent HIV Infection

NCT00004579
View directory record Official record
Conditions
HIV Infections, HIV Seronegativity
Interventions
gp160 MN/LAI-2, ALVAC-HIV MN120TMG (vCP205)
Biological
Lead sponsor
Walter Reed Army Institute of Research (WRAIR)
Federal
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1998
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 23, 2026, 10:53 AM EDT
Completed Phase 1 Interventional

Safety, Tolerability, and Anti-HIV Activity of DMP 266 (Efavirenz) in Combination With Nelfinavir in HIV-Positive Children

NCT00000893
View directory record Official record
Conditions
HIV Infections
Interventions
Nelfinavir mesylate, Efavirenz
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Months to 16 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
25
States / cities
Long Beach, California • Los Angeles, California • Oakland, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Jul 23, 2026, 10:53 AM EDT
Completed Phase 1 Interventional

A Multicenter Study To Determine Foscarnet Dose Response in HIV Infected Patients With PGL and/or Constitutional Disease

NCT00000729
View directory record Official record
Conditions
HIV Infections
Interventions
Foscarnet sodium
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1992
U.S. locations
11
States / cities
Los Angeles, California • San Diego, California • Minneapolis, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Jul 23, 2026, 10:53 AM EDT
Completed Phase 2 Interventional

A Study to Compare Three Doses of T-20 When Given in Combination With Abacavir, Amprenavir, Ritonavir, and Efavirenz to HIV-Infected Adults

NCT00002239
View directory record Official record
Conditions
HIV Infections
Interventions
Enfuvirtide, Ritonavir, Abacavir sulfate, Amprenavir, Efavirenz
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
20
States / cities
Beverly Hills, California • Los Angeles, California • Palm Springs, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2005 · Synced Jul 23, 2026, 10:53 AM EDT
Completed Phase 1 Interventional

A Study of Zidovudine Plus Acyclovir in HIV-Infected Patients

NCT00001010
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Acyclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
19 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1990
U.S. locations
3
States / cities
Los Angeles, California • San Diego, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Jul 23, 2026, 10:53 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study of Chlorhexidine in the Prevention of HIV-1 Transmission From Mothers to Their Babies

NCT00006075
View directory record Official record
Conditions
HIV Infections
Interventions
Chlorhexidine gluconate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2007
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 29, 2008 · Synced Jul 23, 2026, 10:53 AM EDT
Completed Phase 1 Interventional

A Study of LXR015-1 in HIV-Infected Patients

NCT00002365
View directory record Official record
Conditions
HIV Infections
Interventions
LXR015-1
Drug
Lead sponsor
LXR Biotechnology
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 23, 2026, 10:53 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid Withdrawal

NCT04470050
View directory record Official record
Conditions
Opioid Withdrawal
Interventions
Dexmedetomidine, Placebo
Drug
Lead sponsor
BioXcel Therapeutics Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Miami Lakes, Florida • Marlton, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Jul 23, 2026, 10:53 AM EDT
Not listed Phase 1 Interventional

The Safety and Effectiveness of PMPA Prodrug in HIV-Infected Patients

NCT00002396
View directory record Official record
Conditions
HIV Infections
Interventions
Tenofovir disoproxil fumarate
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
San Francisco, California • Baltimore, Maryland • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 23, 2026, 10:53 AM EDT
Completed Phase 1 Interventional

A Study of AL721 in HIV-Infected Patients With Swollen Lymph Nodes

NCT00001012
View directory record Official record
Conditions
HIV Infections
Interventions
AL 721
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
9
States / cities
Los Angeles, California • New Orleans, Louisiana • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Jul 23, 2026, 10:53 AM EDT
Completed Phase 1 Interventional

Safety and Effectiveness of Giving Indinavir Plus Stavudine Plus Lamivudine to HIV-Infected Children

NCT00000901
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Lamivudine, Stavudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 15 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
18
States / cities
La Jolla, California • San Francisco, California • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Jul 23, 2026, 10:53 AM EDT
Completed Phase 1 Interventional

Safety and Effectiveness of Combining Hydroxyurea (HU) With Didanosine (ddI) and Stavudine (d4T) for Treatment of HIV-Infected Adults

NCT00002427
View directory record Official record
Conditions
HIV Infections
Interventions
Hydroxyurea, Stavudine, Didanosine
Drug
Lead sponsor
Research Institute for Genetic and Human Therapy
Other
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
18
States / cities
Los Angeles, California • San Francisco, California • Stamford, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 23, 2026, 10:53 AM EDT
Completed Phase 3 Interventional

A Comparison of Two Dose Levels of Indinavir Combined With Two Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTIs) in HIV-Infected Patients

NCT00002406
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
16 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
29
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 23, 2026, 10:53 AM EDT
Completed Phase 1 Interventional

A Study on the Effect of Chemotherapy Combined With Anti-HIV Drugs in HIV-Positive Patients

NCT00000899
View directory record Official record
Conditions
HIV Infections
Interventions
Nelfinavir mesylate, Lamivudine, Filgrastim, Stavudine, Cyclophosphamide
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2001
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Jul 23, 2026, 10:53 AM EDT
Not listed Phase 2 Interventional

Safety and Effectiveness of Adding Adefovir Dipivoxil and Nelfinavir to the Anti-HIV Therapy of HIV-Infected Children

NCT00002219
View directory record Official record
Conditions
HIV Infections
Interventions
Nelfinavir mesylate, Levocarnitine, Adefovir dipivoxil
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
3 Months to 16 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
7
States / cities
St. Petersburg, Florida • New Orleans, Louisiana • Great Neck, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 23, 2026, 10:53 AM EDT
Completed Phase 1 Interventional

A Phase I Safety, Efficacy, and Pharmacokinetic Study of 2',3'-Dideoxyinosine (ddI) Administered Twice Daily to Patients With AIDS or AIDS Related Complex

NCT00000710
View directory record Official record
Conditions
HIV Infections
Interventions
Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1990
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Jul 23, 2026, 10:53 AM EDT